| Description | CIAC001, a pyruvate kinase PKM2 inhibitor, exhibits anti-neuroinflammatory properties. It effectively suppresses LPS-induced production of proinflammatory nitric oxide (NO) and provides protection to immunologically active BV-2 cells with an IC50 value of 2.5 μM. Additionally, CIAC001 demonstrates anti-neuroinflammation effects in mouse models and attenuates chronic morphine-induced addiction [1]. |
| In vitro | CIAC001（10 μM；6小时）能有效抑制BV-2细胞在LPS（200 ng/mL）诱导下的小胶质细胞形态变化[1]。 |
| In vivo | CIAC001（20 μg/kg及0.2 mg/kg，腹腔注射，日均一次，连续7天）以剂量依赖的方式减轻了吗啡依赖小鼠经Naloxone诱发的戒断跳跃现象，并有效抑制了由吗啡引起的行为敏化的发展[1]。此外，以20 mg/kg剂量腹腔注射CIAC001，每日一次，连续7天仿真的Y迷宫测试中未观察到记忆衰退或认知功能障碍[1]。 |
| molecular weight | 339.43 |
| Molecular formula | C20H25N3O2 |
| CAS | 2649154-82-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |